Description

BRAVECTO CHEWABLE TAB 1000 MG

Indications

BRAVECTO Chewable Tab 1000 mg is indicated for the treatment and prevention of flea infestations and the control of tick infestations in dogs. It is effective against various species of ticks, including the Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Dermacentor variabilis (American dog tick). This product is suitable for dogs weighing between 22 to 44 pounds (10 to 20 kg) and is recommended for use in dogs over 6 months of age.

Mechanism of Action

BRAVECTO contains the active ingredient fluralaner, which belongs to a new class of insecticides known as isoxazolines. Fluralaner works by inhibiting the function of the gamma-aminobutyric acid (GABA) and glutamate-gated chloride channels in the nervous systems of fleas and ticks. This leads to hyperexcitation of the nervous system, resulting in paralysis and death of the parasites. The rapid onset of action and prolonged duration of efficacy make BRAVECTO a convenient option for pet owners seeking long-term protection against these ectoparasites.

Pharmacological Properties

Fluralaner is absorbed quickly after oral administration, with peak plasma concentrations occurring within a few hours. The half-life of fluralaner in dogs is approximately 12 days, allowing for sustained efficacy against fleas and ticks for up to 12 weeks. The drug is primarily metabolized in the liver and excreted mainly in the feces. BRAVECTO is safe for use in dogs when administered at the recommended dosage, and it has a low potential for toxicity in non-target species.

Contraindications

BRAVECTO should not be used in dogs that are hypersensitive to fluralaner or any of the excipients in the formulation. It is contraindicated in puppies younger than 6 months of age and in dogs weighing less than 10 kg (22 lbs). Additionally, caution should be exercised when administering BRAVECTO to dogs with a history of seizures or neurological disorders, as the safety of fluralaner in these populations has not been established.

Side Effects

BRAVECTO is generally well tolerated in dogs; however, some side effects may occur. Commonly reported side effects include vomiting, diarrhea, decreased appetite, lethargy, and excessive salivation. In rare cases, neurological signs such as tremors, ataxia, or seizures may occur. If any severe side effects are observed, pet owners should seek veterinary attention immediately. It is essential to monitor dogs after administration to ensure their safety and well-being.

Dosage and Administration

The recommended dosage of BRAVECTO Chewable Tab is 25 to 56 mg of fluralaner per kg of body weight, administered as a single dose. For dogs weighing between 22 to 44 pounds (10 to 20 kg), the 1000 mg tablet is appropriate. The chewable tablet can be given directly to the dog or mixed with food. It is advisable to administer BRAVECTO at regular intervals of 12 weeks for optimal efficacy against flea and tick infestations. Always consult a veterinarian for the appropriate dosage and administration guidelines tailored to the individual dog’s needs.

Interactions

Currently, there are no known significant drug interactions with fluralaner. However, it is essential to inform the veterinarian of any other medications or supplements the dog is currently taking to avoid potential adverse effects. Caution should be exercised when using BRAVECTO in conjunction with other insecticides or medications that affect the central nervous system. Always consult a veterinarian before combining treatments.

Precautions

Before administering BRAVECTO, a thorough veterinary examination is recommended to assess the dog’s health status. Special attention should be given to dogs with a history of seizures or neurological disorders, as the safety of fluralaner in these cases has not been fully established. Pregnant or lactating dogs should only be treated with BRAVECTO if the benefits outweigh the risks, as safety during pregnancy and lactation has not been evaluated. Always follow the veterinarian’s recommendations regarding the use of BRAVECTO and monitor the dog for any adverse reactions post-administration.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of BRAVECTO in controlling flea and tick infestations in dogs. In one study, BRAVECTO was shown to provide 100% efficacy against fleas within 12 hours of administration and maintained over 90% efficacy against fleas for up to 12 weeks. Similarly, it demonstrated significant efficacy against various tick species, with a rapid onset of action. The safety profile of BRAVECTO has also been evaluated in multiple studies, confirming its tolerability in healthy dogs. These studies support the use of BRAVECTO as a reliable option for flea and tick prevention in dogs.

Conclusion

BRAVECTO Chewable Tab 1000 mg is an effective and convenient option for the treatment and prevention of flea and tick infestations in dogs. With its novel mechanism of action and long-lasting efficacy, it provides pet owners with peace of mind in managing ectoparasite infestations. However, it is essential to follow the recommended dosage and consult a veterinarian for any concerns regarding the use of this product. Regular monitoring of the dog’s health and response to treatment is crucial for ensuring optimal outcomes.